EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis

L R Caley, H H Jarosz-Griffiths, L Smith, L Gale, J Barrett, L Kinsey, V Davey, M Nash, A M Jones, J L Whitehouse, D Shimmin, R A Floto und 2 weitere

Journal of Cystic Fibrosis · 2023

DOI: 10.1016/j.jcf.2023.06.010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von L R Caley und 13 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Medical Research at St James's, University of Leeds, UK; Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, L…. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elexacaftor/Tezacaftor/Ivacaftor (ETI) modulator therapy is often associated with increased body mass index (BMI) in people with cystic fibrosis (CF). This is thought to reflect improved clinical stability and increased appetite and nutritional intake. We explored the change in BMI and nutritional intake following ETI modulator therapy in adults with CF. METHODS: Dietary intake, measured with myfood24®, and BMI were collected from adults with CF at baseline and follow-up as part of an observational study. Changes in BMI and nutritional intake in participants who commenced ETI therapy between time points were assessed. To contextualize findings, we also assessed changes in BMI and nutritional intake between study points in a group on no modulators. RESULTS: In the pre and post ETI threapy group (n = 40), BMI significantly increased from 23.0 kg/m2 (IQR 21.4, 25.3) at baseline to 24.6 kg/m2 (IQR 23.0, 26.7) at follow-up (p 0.05), a median of 28 weeks apart (range 20-76 weeks). CONCLUSIONS: These findings tentatively suggest that the increase in BMI with ETI therapy may not simply be attributable to an increase in oral intake. Further exploration into the underlying aetiology of weight gain with ETI therapy is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAdultHumansBody Mass IndexEatingCystic Fibrosis Transmembrane Conductance RegulatorMutationBenzodioxolesAminophenolsPyrazolesPyridinesPyrrolidinesQuinolonesIndoles

Stichwörter der Autor:innen

Body mass indexCFTR modulatorsCystic fibrosisElexacaftor/ivacaftor/tezacaftorEnergy expenditureNutritional intake

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesAminophenolselexacaftorPyrazolesPyridinesPyrrolidinesivacaftorQuinolonestezacaftor

Autor:innen und Institutionen

  • Leeds Institute of Medical Research at St James's, University of Leeds, UK; Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address: l.r.caley@leeds.ac.uk.
  • Leeds Institute of Medical Research at St James's, University of Leeds, UK.
  • Leeds Institute of Health Sciences, University Hospital, University of Leeds, UK.
  • Cambridge Centre for Lung Infection, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
  • West Midlands Regional Adult CF Centre, University Hospitals Birmingham NHS, Foundation Trust, Birmingham, UK.
  • Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust, UK.

Förderung

  • Cystic Fibrosis Trust

Zitieren

APA

Caley, L. R., Jarosz-Griffiths, H. H., Smith, L., Gale, L., Barrett, J., Kinsey, L., Davey, V., Nash, M., Jones, A. M., Whitehouse, J. L., Shimmin, D., Floto, R. A., White, H., & Peckham, D. G. (2023). Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.06.010

Vancouver

Caley LR, Jarosz-Griffiths HH, Smith L, Gale L, Barrett J, Kinsey L, et al. Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.06.010

BibTeX
@article{Caley2023,
  author = {Caley, L R and Jarosz-Griffiths, H H and Smith, L and Gale, L and Barrett, J and Kinsey, L and Davey, V and Nash, M and Jones, A M and Whitehouse, J L and Shimmin, D and Floto, R A and White, H and Peckham, D G},
  title = {Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  doi = {10.1016/j.jcf.2023.06.010}
}
Kostenlos starten →